14th Congress of European Crohn’s and Colitis Organisation (ECCO) 2019

Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis

Crohn’s & Colitis Congress 2019

Olorinab, a Peripherally Restricted, Highly Selective Agonist of the Cannabinoid Receptor Type 2 for the Management of Visceral Pain in Inflammatory Bowel Disease (IBD)—Preclinical and Early Clinical Development

International Association for the Study of Pain (IASP) World Congress 2018

APD371, a Peripherally Restricted, Highly Selective, Full Agonist of the Cannabinoid Receptor 2 (CB2) Receptor, Reduces Colitis-Induced Visceral Hypersensitivity in Rats

Congress: American Pain Society (APS) Annual Scientific Summit 2018

APD371: A Potent, Highly Selective, Full Agonist of the Human CB2 Receptor With Sustained Analgesic Effects in Rodents

Safety, Tolerability, and Pharmacokinetics of APD371, a Highly Selective CB2 Agonist, in Healthy Adults

Discovery of APD371 2017

Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain

ASPET at Experimental Biology (EB) 2017

Etrasimod, a Novel Sphingosine-1-Phosphate Receptor (S1PR1) Modulator, Lacks Functional Activity at S1P2 Receptors

Etrasimod (APD334), an Oral, Next-Generation Sphingosine-1-Phosphate Receptor Modulator Inhibits the Development of Colitis in Lymphoid-Null Mice Injected With Colitogenic CD4+ T Cells

Functional Activity of Etrasimod and a Diverse Panel of Sphingosine-1-Phosphate Receptor (S1PR1) Modulators at S1P4 Receptors

Autoimmunity Reviews 16 (2‍0‍1‍7)495-503

Modulation of sphingosine-1-phosphate in inflammatory bowel disease

1 2 3 4

For Medical Information, contact us at medinfo@arenapharm.com